Membranoproliferative glomerulonephritis future or investigational therapies

Jump to navigation Jump to search


Todays treatment of Membranoproliferative Glomerulonephritis is going to focus on monoclonal antibodies such as Rituximab, which is one of the most effective treatment.[1]

Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis future or investigational therapies

CDC on Membranoproliferative glomerulonephritis future or investigational therapies

Membranoproliferative glomerulonephritis future or investigational therapies in the news

Blogs on Membranoproliferative glomerulonephritis future or investigational therapies

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis future or investigational therapies

References

  1. Michael Rudnicki. "Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies". BioMed Research International.

Template:WH Template:WS